Treatment of Inoperable Liver Cancer with Pegylated Liposomal Doxorubicin
Author Information
Author(s): Valle J W, Dangoor A, Beech J, Sherlock D J, Lee S M, Scarffe J H, Swindell R, Ranson M
Primary Institution: Christie Hospital NHS Trust
Hypothesis
Does pegylated liposomal doxorubicin (PLD) show efficacy in treating inoperable hepatocellular carcinoma?
Conclusion
Pegylated liposomal doxorubicin showed almost no activity in patients with advanced hepatocellular carcinoma.
Supporting Evidence
- The response rate was 0%, with stable disease in 19% of patients.
- The median time to progression was 2.4 months.
- The 1-year survival rate was 25%.
Takeaway
The study tested a new cancer drug on patients with liver cancer, but it didn't work well at all.
Methodology
An open-label, phase II study was conducted with chemotherapy-naïve patients who had histologically proven hepatocellular carcinoma.
Limitations
The study was closed due to not reaching the minimal threshold of activity.
Participant Demographics
{"total_patients":16,"age":{"median":56,"range":"23-65"},"sex":{"male":12,"female":4},"performance_status":{"0":3,"1":13},"tumor_histology":{"hepatocellular_carcinoma":13,"fibrolamellar_type":3},"tumor_stage":{"4A":7,"4B":9}}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website